1. Home
  2. IMCR vs HMN Comparison

IMCR vs HMN Comparison

Compare IMCR & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • HMN
  • Stock Information
  • Founded
  • IMCR 2008
  • HMN 1945
  • Country
  • IMCR United Kingdom
  • HMN United States
  • Employees
  • IMCR N/A
  • HMN N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • HMN Property-Casualty Insurers
  • Sector
  • IMCR Health Care
  • HMN Finance
  • Exchange
  • IMCR Nasdaq
  • HMN Nasdaq
  • Market Cap
  • IMCR 1.8B
  • HMN 1.9B
  • IPO Year
  • IMCR 2021
  • HMN 1991
  • Fundamental
  • Price
  • IMCR $33.42
  • HMN $45.76
  • Analyst Decision
  • IMCR Buy
  • HMN Buy
  • Analyst Count
  • IMCR 8
  • HMN 5
  • Target Price
  • IMCR $57.00
  • HMN $46.75
  • AVG Volume (30 Days)
  • IMCR 288.3K
  • HMN 192.3K
  • Earning Date
  • IMCR 11-05-2025
  • HMN 11-03-2025
  • Dividend Yield
  • IMCR N/A
  • HMN 3.05%
  • EPS Growth
  • IMCR N/A
  • HMN 71.62
  • EPS
  • IMCR N/A
  • HMN 3.38
  • Revenue
  • IMCR $356,145,000.00
  • HMN $1,649,200,000.00
  • Revenue This Year
  • IMCR $29.67
  • HMN $7.38
  • Revenue Next Year
  • IMCR $11.12
  • HMN $6.25
  • P/E Ratio
  • IMCR N/A
  • HMN $13.56
  • Revenue Growth
  • IMCR 26.78
  • HMN 6.01
  • 52 Week Low
  • IMCR $23.15
  • HMN $33.65
  • 52 Week High
  • IMCR $39.33
  • HMN $47.81
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 44.21
  • HMN 51.63
  • Support Level
  • IMCR $35.33
  • HMN $45.44
  • Resistance Level
  • IMCR $36.76
  • HMN $47.81
  • Average True Range (ATR)
  • IMCR 1.48
  • HMN 0.81
  • MACD
  • IMCR -0.12
  • HMN -0.17
  • Stochastic Oscillator
  • IMCR 24.65
  • HMN 24.63

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

Share on Social Networks: